A patient on olmesartan 20 mg has orthostatic hypotension with a drop in blood pressure from seated 118/74 mm Hg to standing 106/52 mm Hg; how should this be managed?

Management of Orthostatic Hypotension in a Patient on Olmesartan

Your patient meets diagnostic criteria for classic orthostatic hypotension (12 mmHg systolic and 22 mmHg diastolic drop), and olmesartan is the likely culprit—you should discontinue or reduce the dose of olmesartan and switch to an alternative antihypertensive agent. 1

Confirming the Diagnosis

Your patient's blood pressure drop from 118/74 sitting to 106/52 standing represents:

• Systolic drop of 12 mmHg (meets the ≥20 mmHg threshold partially)
• Diastolic drop of 22 mmHg (exceeds the ≥10 mmHg threshold) 1, 2

This definitively meets ACC/AHA/HRS criteria for classic orthostatic hypotension (sustained reduction within 3 minutes of standing). 1, 3

Critical assessment needed:

• Does the patient have symptoms (lightheadedness, dizziness, weakness, visual disturbances, coat hanger pain)? 4, 5
• Measure blood pressure at 1 and 3 minutes after standing to fully characterize the pattern 6
• Check for volume depletion, dehydration, or concurrent diuretic use 7, 8

Olmesartan as the Causative Agent

Olmesartan directly causes orthostatic hypotension through multiple mechanisms:

The FDA label explicitly warns that olmesartan causes "symptomatic hypotension in volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics)" and states that treatment should be "initiated under close medical supervision" with consideration of "starting at a lower dose." 8

Key pathophysiology: Angiotensin receptor blockers like olmesartan inhibit the renin-angiotensin-aldosterone system, impairing the compensatory vasoconstriction needed to maintain blood pressure during postural changes. 8, 9, 10

Immediate Management Steps

1. Discontinue or Reduce Olmesartan Dose

This is your first-line intervention. 9, 11

• Option A (Preferred): Stop olmesartan entirely and switch to an alternative antihypertensive class less likely to cause orthostatic hypotension (calcium channel blocker or thiazide diuretic at low dose) 9, 11
• Option B: Reduce olmesartan from 20 mg to 10 mg (or 2.5-5 mg) if blood pressure control requires continuation 8

The FDA label confirms olmesartan doses of 20 mg produce significant blood pressure reductions (10/6 mmHg), and lower doses may provide adequate control with less orthostatic effect. 8

2. Assess for Volume Depletion

Check for:

• Concurrent diuretic use (stop or reduce dose) 7, 8
• Inadequate fluid intake 7
• Recent illness with fluid losses 5

The FDA specifically warns about olmesartan causing hypotension in volume-depleted states. 8

3. Rule Out Neurogenic Causes

Determine if this is drug-induced OH versus neurogenic OH:

• Drug-induced OH: Heart rate typically increases appropriately (>15 bpm rise) with standing 2, 5
• Neurogenic OH: Blunted heart rate response (<15 bpm rise) suggests autonomic dysfunction 2, 5

If neurogenic features are present (Parkinson's disease, diabetes with neuropathy, pure autonomic failure), referral for autonomic testing may be warranted. 2

Non-Pharmacologic Interventions (While Adjusting Medications)

Implement these immediately:

• Increase salt intake to 6-9 grams daily (1-2 teaspoons) unless contraindicated by heart failure 7, 12

  • Note: The 2025 AHA/ACC hypertension guidelines state "dietary sodium reduction may be contraindicated in patients with severe, symptomatic orthostatic hypotension" 12

• Increase fluid intake to 2-2.5 liters daily 7, 5

• Physical counterpressure maneuvers: Leg crossing, muscle tensing, or squatting when symptoms occur 7, 5

• Compression garments: Thigh-high or abdominal binders (at least 15-20 mmHg compression) 7, 5

• Avoid triggers: Prolonged standing, hot environments, large meals, rapid position changes 4, 5

Pharmacologic Treatment (Only if Symptoms Persist After Medication Adjustment)

If orthostatic hypotension persists despite stopping/reducing olmesartan and implementing non-pharmacologic measures:

First-Line Agents:

• Midodrine 2.5-10 mg three times daily (alpha-1 agonist; avoid dosing after 6 PM due to supine hypertension risk) 7, 5, 13
• Droxidopa 100-600 mg three times daily (synthetic norepinephrine precursor) 7, 5

Second-Line Agent:

• Fludrocortisone 0.1-0.3 mg daily (mineralocorticoid; increases plasma volume but may worsen supine hypertension) 7, 5, 13

Critical caveat: These agents are typically reserved for neurogenic orthostatic hypotension, not drug-induced OH. 7, 11 In your patient with drug-induced OH from olmesartan, medication adjustment should resolve the problem without need for these agents.

Monitoring Plan

After discontinuing/reducing olmesartan:

• Recheck orthostatic vital signs in 1-2 weeks 5, 11
• Monitor seated/supine blood pressure to ensure hypertension remains controlled 11
• Symptoms should improve within days to weeks of stopping the offending agent 9, 14

Special Consideration: Sprue-like Enteropathy

While addressing the orthostatic hypotension, be aware that olmesartan uniquely causes severe chronic diarrhea with villous atrophy (sprue-like enteropathy) months to years after initiation. 8, 14 If your patient develops chronic diarrhea, this is another compelling reason to discontinue olmesartan permanently. 8, 14